Currently more than 200,000 patients in the UK are living with non-healing wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and post-surgical wounds. Treating patients with chronic wounds costs the NHS between £2.3-3.1 billion a year in associated costs including nursing time, dressings, hospital admissions, pain relief and often unnecessary amputations.
Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing in wounds such as venous leg ulcers, by 75% compared to standard care. The treatment also reduces pain by an average of 68% within two weeks.
Independent clinical studies have shown that, when added to standard care, Granulox could save the NHS an average of £2,330 for every diabetic foot ulcer patient and £1,469 for chronic wound patients after six months.
Alistair Copley, Wound Care Manager, infirst Healthcare says, “This is good news for both patients and healthcare professionals. The assessment process undertaken by the NHS Prescription Service is in-depth, challenging and rigorous. Treatments that pass this level of scrutiny have to prove both clinical and cost effectiveness. We are pleased that Granulox has received this recognition and expect to see it being administered across the UK over the coming months.”
Sharon Bateman, Lead Advanced Nurse Practitioner, Northumberland NHS, said: “The impact of chronic wounds is not only physical, but social and emotional too. Patients need to know that innovations like this are available to them. Granulox helps wounds to heal, reducing pain, time spent with nurses, and patients can even administer the treatment themselves with support, regaining confidence and independence.”